LBA79 GEMSTONE-303: Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

作者：Xiao Zhang, J. Wang, Guoping Wang, Y. Zhang, Qingxia Fan, Liao Chuang-xin, Chengping Hu, Meili Sun, Yun Wan, Sanyuan Sun, Jun Wang, Li Zhang, Yongqian Shu, Jiefeng Luo, Dalong Zhu, Haiying Wang, Yi Xu, Qiang Shi, J. Joshua Yang, Lin Shen · 发表于：Annals of Oncology · 年份：2023 · DOI：10.1016/j.annonc.2023.10.080 · 被引用次数：31 · 研究领域：Gastric Cancer Management and Outcomes、Esophageal Cancer Research and Treatment、Colorectal Cancer Treatments and Studies